Progenitor Cells for High Endothelium in the Immune Response

免疫反应中高内皮的祖细胞

基本信息

项目摘要

PROJECT SUMMARY / ABSTRACT High endothelial venules (HEV) are specialized post capillary portals for lymphocyte entry into lymphoid tissues and sites of chronic inflammation from the blood. They regulate immune cell trafficking in physiologic and pathologic settings including autoimmune diseases and cancer. HEV in lymph nodes draining sites of immune challenge proliferate extensively to support enhanced lymphocyte recruitment, but the endothelial precursors that give rise to high endothelium and the molecular pathways that control their proliferation and differentiation are unclear. Our transcriptomic and immunologic studies reveal that capillary endothelial cells (CapEC) express multiple markers classically associated with stem and progenitor cells, leading to the hypothesis that capillary phenotype EC comprise a population of stem cell-like blood endothelial progenitors that contribute to HEV expansion during the immune response. Under Aim 1 we will apply state-of-the-art single cell immunofluorescence and high dimensional mass label (CyTOF) flow cytometry to uncover the diversity of EC subsets in LN and in extra lymphoid sites of immune cell recruitment, define the kinetics and subset-specificity of their proliferative responses to immune challenge, and reveal the time course of emergence of transitional phenotypes leading to the amplification and maturation of functional HEV. Trajectory analyses will reveal developmental relationships of identified subsets including identified progenitors, and immunofluorescence histology and confocal tissue imaging will define their location within the vasculature. In Aim 2, innovative fate mapping approaches will elucidate precursor-product relationships among BEC subsets and will define clonal contributions of precursors to capillary and high endothelium. Aim 3 will apply transcriptional profiling of induced EC subsets in combination with pan-EC and novel capillary EC-specific inducible gene targeting systems to define molecular mechanisms of HEV homeostasis and pathways regulating progenitor cell activation, amplification and contribution to HEV expansion in the immune response. Comprehensive phenotypic analyses of blood endothelial cell subsets and their responses to immunization will open up new areas of investigation in vascular biology and immunology. Elucidation of the mechanisms of endothelial cell specialization and homeostasis, including mechanisms regulating endothelial cells that control lymphocyte traffic, will lead to novel targets and approaches for the control of autoimmune inflammation and for therapeutic regulation of immune cell traffic for vaccination and cancer immunity.
项目摘要/摘要 高内皮微静脉(HEV)是淋巴细胞进入淋巴组织的特殊毛细血管后通道 以及血液中的慢性炎症部位。它们调节免疫细胞在生理和免疫系统中的运输 病理环境包括自身免疫性疾病和癌症。HEV在淋巴引流部位的免疫 挑战广泛增殖以支持增强的淋巴细胞募集,但内皮细胞前体 导致高内皮细胞和控制其增殖和分化的分子途径 都不清楚。我们的转录和免疫学研究表明,毛细血管内皮细胞(CapEC)表达 传统上与干细胞和祖细胞相关的多个标记,导致了毛细血管 表型EC包括一群干细胞样血内皮祖细胞,这些细胞对HEV有贡献 在免疫反应过程中扩张。在目标1下,我们将应用最先进的单一电池 免疫荧光和高维质量标记(CyTOF)流式细胞术揭示EC多样性 LN和免疫细胞募集的淋巴外部位的亚群决定了免疫细胞募集的动力学和亚群特异性 它们对免疫攻击的增殖反应,揭示了过渡性T细胞出现的时间过程 导致功能性HEV扩增和成熟的表型。弹道分析将揭示 已鉴定亚群的发育关系,包括已鉴定的祖细胞和免疫荧光 组织学和共聚焦组织成像将确定它们在血管系统中的位置。在目标2中,创新的命运 作图方法将阐明BEC亚群之间的前体-产物关系,并将定义克隆 前体对毛细血管和高级内皮的贡献。AIM 3将应用诱导的转录特征分析 EC亚群与PAN-EC和新型毛细血管EC特异性诱导基因打靶系统相结合 明确HEV动态平衡的分子机制和调节祖细胞激活的途径 HEV在免疫反应中的扩增和贡献。 血液内皮细胞亚群的综合表型分析及其对免疫的反应 开拓血管生物学和免疫学研究的新领域。阐明其致病机制 内皮细胞特化和稳态,包括调控内皮细胞控制的机制 淋巴细胞运输,将导致新的靶点和方法来控制自身免疫性炎症和 疫苗接种和癌症免疫的免疫细胞运输的治疗性调节。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EUGENE C BUTCHER其他文献

EUGENE C BUTCHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EUGENE C BUTCHER', 18)}}的其他基金

Tumor and Immune Programming of Tumor-AssociatedEndothelium
肿瘤和肿瘤相关内皮细胞的免疫编程
  • 批准号:
    10532149
  • 财政年份:
    2018
  • 资助金额:
    $ 50.97万
  • 项目类别:
Tumor and Immune Programming of Tumor-AssociatedEndothelium
肿瘤和肿瘤相关内皮细胞的免疫编程
  • 批准号:
    10303033
  • 财政年份:
    2018
  • 资助金额:
    $ 50.97万
  • 项目类别:
Tumor and Immune Programming of Tumor-Associated Endothelium
肿瘤和肿瘤相关内皮细胞的免疫编程
  • 批准号:
    10054980
  • 财政年份:
    2018
  • 资助金额:
    $ 50.97万
  • 项目类别:
Progenitor Cells for High Endothelium in the Immune Response
免疫反应中高内皮的祖细胞
  • 批准号:
    10223152
  • 财政年份:
    2017
  • 资助金额:
    $ 50.97万
  • 项目类别:
Progenitor Cells for High Endothelium in the Immune Response
免疫反应中高内皮的祖细胞
  • 批准号:
    10592196
  • 财政年份:
    2017
  • 资助金额:
    $ 50.97万
  • 项目类别:
Transcriptional Profiling of Human High Endothelial Venules
人类高内皮小静脉的转录谱
  • 批准号:
    9212639
  • 财政年份:
    2016
  • 资助金额:
    $ 50.97万
  • 项目类别:
Intestinal Lymphocyte Trafficking
肠道淋巴细胞贩运
  • 批准号:
    9206459
  • 财政年份:
    2016
  • 资助金额:
    $ 50.97万
  • 项目类别:
Intestinal Lymphocyte Trafficking
肠道淋巴细胞贩运
  • 批准号:
    9894708
  • 财政年份:
    2016
  • 资助金额:
    $ 50.97万
  • 项目类别:
Intestinal Lymphocyte Trafficking
肠道淋巴细胞贩运
  • 批准号:
    8849684
  • 财政年份:
    2016
  • 资助金额:
    $ 50.97万
  • 项目类别:
Chemerin in Tumor Immunity and Surveillance
Chemerin 在肿瘤免疫和监测中的作用
  • 批准号:
    9041803
  • 财政年份:
    2015
  • 资助金额:
    $ 50.97万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.97万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 50.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了